1. Goetz CG: Neurotoxins in Clinical Practice. New York, Spectrum Publications, 198 5.

2. Hartman D: Neuropsychological Toxicology: Identification and Assessment of Human Neurotoxic Syndromes. New York, Pergamon Press, 19 88.

3. Bolla KI: Neuropsychological evaluation for detecting alterations in the central nervous system after chemical exposure. Regul Toxicol Pharmacol 1996;24:548-55■.

4. Bolla-Wilson K, Bleecker ML: Neuropsychological impairment following inorganic arsenic exposure. j Occup Med 1987;29:500-503

5. Wittmers Jr LE, Wallgren J, Alich A, et al: Lead in bone. IV. Distribution of lead in the human skeleton. Arch Environ Health 1988;43:381-39-,

6. Somervaille LJ, Chettle DR, Scott MC, et al: In vivo tibia lead measurements as an index of cumulative exposure in occupationally exposed subjects. Br j Ind Med 1988;45:174-181

7. Davis JM, Elias RW, Grant LD: Current issues in human lead exposure and future development in the regulation of lead. Neurotoxicology 1993;14:15-28

8. Annest JL, Pirkle JL, Makuc D, et al: Chronological trend in blood levels between 1976 and 1980. n Engl j Med 1983;308:1373-1377

9. Bellinger D, Levinton A, Waternaux C, et al: Longitudinal analyses of prenatal and postnatal lead exposure and early cognitive development. n Engl j Med 1987;316:1037-1043

10. Needleman HL, Schell A, Bellinger D, et al: The long-term effects of exposure to low doses of lead in childhood: An 11 year follow-up report. n Engl j Med 1990;322:83-88

11. Todd AC, McNeill FE, Palethorpe JE, et al: In vivo x-ray fluorescence of lead in bone using K x-ray excitation with 109 Cd sources: Radiation and dosimetry studies. Environ Res 1992;57:117-132

12. Hanninen H, Hernberg S, Mantere P, et al: Psychological performance of subjects with low exposure to lead. j Occup Med 1978;20:683

13. Baker EL, Feldman RG, White RF, et al: The role of occupational lead exposure in the genesis of psychiatric and behavioral disturbances. Acta Psychiat Scand 1983;303:38-48

14. Ryan CM, Morrow L, Parkinson D, et al: Low level lead exposure and

neuropsychological functioning in blue collar males. Int j Neurosci 1987;36:29-39

15. Balbus-Kornfeld J, Stewart W, Bolla KI, et al: The effect of cumulative lead exposure on neurobehavioral test performance in adults. j Occup Environ Med 1995;52:2-12

16. Schwartz BS, Bolla KI, Stewart W, et al: Decrements in neurobehavioral performance associated with mixed exposure to organic and inorganic lead. Am j Epidemiol 1993;137:1006-102-.

17. Mena I, Court J, Fuenzalida S, et al: Modification of chronic manganese poisoning treatment with L-dopa or 5-OH tryptophane. n Engl j Med 1970;282:5-10

18. Cotzias GC, Horiuchi K, Fuenzalida S, et al: Chronic manganese poisoning: Clearance of tissue manganese concentrations with persistence of the neurological picture. Neurology 1968;18:376-382

19. Shiraki H: Neuropathological aspects of organic mercury intoxication. In Vinken PJ, Bruyn GW (eds): Handbook of Clinical Neurology. Amsterdam, North-Holland, 1979, pp 83-1 6.

20. Chang LW, Dyer RS (eds): Handbook of Neurotoxicology. New York, Marcel Dekker, 199..

21. Hormes J, Filley C, Rosenberg N: Neurologic sequelae of chronic solvent vapor abuse. Neurology 1986;36:698-702

22. Bolla KI, Schwartz BS, Stewart W, et al: A comparison of neurobehavioral function in workers exposed to a mixture of organic and inorganic lead and in workers exposed to solvents. Am j Ind Med


23. Cranmer JM, Goldberg L: Human aspects of solvent neurobehavioral effects. Report of the workshop session on clinical and epidemiological topics. Proceedings of the Workshop on Neurobehavioral Effects of Solvents. Neurotoxicology 1986;7:45-56

24. Mittal BV, Desai AP, Khade KR: Methyl alcohol poisoning: An autopsy study of 28 cases. j Postgrad Med 1991;37:9-13

25. Spencer PS, Couri D, Schaumburg HH: N-Hexane and methyl n-butyl ketone. In Spencer PS, Schaumberg HH (eds): Experimental and Clinical Neurotoxicology. Baltimore, Williams & Wilkins, 1980, pp 456- 75.

26. Benignus VA: Neurobehavioral effects of toluene: A review. Neurobehav Toxicol Teratol 1981;3:408-41!..

27. Feldman RG: Trichlorethylene. In Vinken PJ, Bruyn GW (eds): Handbook of Clinical Neurology. Amsterdam, North-Holland, 1979, pp 457-4(4.

28. Min SK: A brain syndrome associated with delayed neuropsychiatric sequelae following acute carbon monoxide intoxication. Acta PsychiatrScand 1986;73:80-86

29. Gordon MF, Mercandetti M: Carbon monoxide poisoning producing purely cognitive and behavioral sequelae. Neuropsychiat Neuropsychol Behav Neurol 1989;2:145-152.

30. McConnell R: Pesticides and Related Compounds. In Rosenstock L, Cullen MR (eds): Textbook of Clinical Occupational and Environmental Medicine. Philadelphia, W.B. Saunders, 1994, pp 847- 65.

31. Senanayake N, et al: Acute polyneuropathy after poisoning by a new organophosphate insectide. n Engl j Med 1982;306:155-157

32. Baker SR, Williamson CF: The Effects of Pesticides on Human Health. Advances in Modern Environmental Toxicology. Princeton, NJ, Princeton Scientific Co, 199 0.

33. Mayersdorf A, Israeli R: Toxic effects of chlorinated hydrocarbon insecticides on the human electroencephalogram. Arch Environ Health 1974;28:159-163

34. Russell FE: Snake venom poisoning. Vet Human Toxicol 1991;33:584-586

35. Rodichok LD, Barron KD: Neurologic complications of bee sting, tick bite, spider bite, and scorpion sting. In Vinken PJ, Bruyn GW (eds): Handbook of Clinical Neurology. Amsterdam, North Holland, 1979, pp 107-1 4.

36. Hovell WH: Tick paralysis: A review. Mayo Clin Proc 1943; 18:39-49 (Abstract)

37. Gueron M, Ilia R, Sofer S: The cardiovascular system after scorpion envenomation. j Toxicol Clin Toxicol 1992;30:245-258.

38. Misra UK, Sharma VP: Peripheral and central conduction studies in neurolathyrism. j Neurol Neurosurg Psychiatry 1994;57:572-577

39. Weaver AL: Lathyrism: A review. Arthritis Rheum 1967;10:470-474

40. Waksman BH: Experimental study of diphtheric polyneuritis. j Neuropathol Exp Neurol 1961;20:35-45

41. Weinstein L: Tetanus. N Engl J Med 1973;289:1293

42. Arnon SS, Midura TF, Damus K, et al: Honey and other environmental risk factors for infant botulism. jPediatr 1979;94:331-336

43. Barrett DH: Endemic food-borne botulism: Clinical experience 1973-1986 at Alaska Native Medical Center. Alaska Med 1991;33:101-108

44. Levine SR, Brust JCM, Futrell N, et al: Cerebrovascular complications of the "crack" form of alkaloidal cocaine. n Engl J Med 1990;323:699

45. Kaku DA, Lowestein DH: Emergence of recreational drug abuse as a major risk factor for stroke in young adults. Ann Intern Med 1990;113:821

46. Sloan MA, Kittner SJ, Rigamonti D, et al: Occurrence of stroke associated with use/abuse of drugs. Neurology 1991;41:135&

47. Krendel DA, Ditter SM, Frankel MR, et al: Biopsy-proven cerebral vasculitis associated with cocaine abuse. Neurology 1991;40:1092

48. Fredericks RK, Lefkowitz DS, Challa VER, et al: Cerebral vasculitis associated with cocaine abuse. Stroke 1991;22:1437

49. Volkow ND, Fowler JS, Wolf AP, et al: Metabolic studies of drugs of abuse. In Harris L (ed): Problems of Drug Dependence 1990. NIDA Research Monograph 105. Washington, DC, Department of Health and Human Services, 1991, p 47.

50. London ED, Cascella NG, Wong DF, et al: Cocaine-induced reduction of glucose utilization in human brain. Arch Gen Psychiatry 1990;47:567-574

51. Rumbaugh CL, Bergeron T, Gang HCH, et al: Cerebral angiographic changes in the drug abuse patient. Radiology 1971,101:335

52. Rothrock JF, Rubenstein R, Lyden PD: Ischemic stroke associated with methamphetamine inhalations. Neurology 1988;38:589-592

53. Rumbaugh CL, Bergeron T, Scanlon RL, et al: Cerebral vascular changes secondary to amphetamine abuse in the experimental animal. Radiology 1971;101:345

54. Rumbaugh CL, Fang HCH, Higgins RE, et al: Cerebral microvascular injury in experimental drug abuse. Invest Radiol 1976;11:382-394

55. Stafford CR, Bodganoff BM, Green L, et al: Mononeuropathy multiplex as complication of amphetamine angiitis. Neurology 1975;25:570-572

56. Martin WR, Sloan JW, Sapira JD, et al: Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971;12:245

57. Pollack MA, Cohen NL, Friedhoff AG: Gilles de la Tourette's syndrome: Familial occurrence and precipitation by methylphenidate therapy. Arch Neurol 1977;34:630-632

58. Bonthala CM, West A: Pemoline induced chorea and Gilles de la Tourette's syndrome. Br J Psychiatry 1983;143:300-302

59. McCann UD, Ridenour A, Shaham Y, Ricaurte G: Serotonin neurotoxicity after (±) 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy): A controlled study in humans. Neuropsychopharmacology 10:129-138

60. Shiffer D, Brignolio F, Giordena MT, et al: Spongiform encephalopathy in addicts inhaling preheated heroin. Clin Neuropathol 1985;4:174

61. Martin WR, Frazer HF: A comparative study of physiological and subjective effects of heroin and morphine administered intravenously in post addicts. J Pharmacol Exp Ther 1961;133:388

62. Lahmeyer HW, Steingold RG: Pentazocine and tripelennamine: A drug abuse epidemic? Int J Addict 1980;15:1219-1232

63. Goodhart LC, Loizou LA, Anderson M: Heroin myelopathy. J Neurol Neurosurg Psychiatry 1982;45:562-563

64. Loizou LA, Boddie HG: Polyradiculoneuropathy associated with heroin abuse. J Neurol Neurosurg Psychiatry 1978;41:855-587

65. Brust JCM, Richter RW: Tetanus in the inner city. ny State J Med 1974;74:1735

66. Davis GC, Williams AC, Markey SP, et al: Chronic Parkinsonism secondary to intravenous injection of neperidine analogs. Psychiatry Res 1979;1:249

67. Langston JW, Ballard P, Teturd JW, et al: Chronic Parkinsonism due to a product of neperidine analog synthesis. Science 1983;219:979-980

68. McCrodden JM, Tipton KF, Sullivan JP: The neurotoxicity of MPTP and the relevance to Parkinson's disease. Pharmacol Toxicol 1990;67:8-13

69. Cadet JL, Ali SF, Rothman RB, et al: Neurotoxicity, drugs of abuse, and the CuZn- superoxide dismutase transgenic mice. MolNeurobiol 1995;11:155-163

70. ACGIH: Threshold Limit Values and Biological Exposure Indices for 1994-1995. Cincinnati, American Conference of Governmental Industrial Hygienists, 199 4.


Headache Happiness

Headache Happiness

Headache Happiness! Stop Your Headache BEFORE IT STARTS. How To Get Rid Of Your Headache BEFORE It Starts! The pain can be AGONIZING Headaches can stop you from doing all the things you love. Seeing friends, playing with the kids... even trying to watch your favorite television shows. And just think of how unwelcome headaches are while you're trying to work.

Get My Free Ebook

Post a comment